**Supplementary Table 1. Dose Comparison for GIII-V immune-related adverse events across different therapies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dose Comparison | | Odds Ratio | 95% Confidence Interval | | p-value |
| ***Iplimumab*** | | | | | |
| 3 mg/kg q3w | 10 mg/kg q3w | 1.32 | 0.70 | 2.50 | 0.39 |
| ***Nivolumab*** | | | | | |
| 10 mg/kg q2w | 10 mg/kg q3w | 0.68 | 0.25 | 1.86 | 0.97 |
| 0.3 mg/kg q2w | 0.3 mg/kg q3w | 0.61 | 0.10 | 3.9 | 0.99 |
| ***Pembrolizumab*** | | | | | |
| 2 mg/kg q3w | 10 mg/kg q3w | 0.95 | 0.82 | 1.11 | 0.42 |
| 2 mg/kg q3w | 10 mg/kg q2w | 0.89 | 0.76 | 1.04 | 0.17 |
| 10 mg/kg q3w | 10 mg/kg q2w | 0.94 | 0.82 | 1.07 | 0.42 |

**Legend to Supplementary Figures:**

**Supplementary Figure 1.** Bootstrap analyses for GIII-V immune-related AEs across different treatments.

**Supplementary Figure 2.** Bootstrap analysis of overall response rates for NSCLC.

**Supplementary Figure 3.** Bootstrap analysis of overall response rates for RCC.